FindTrial
Sign In

Human Vasodilatory Effect of GLP-1

Vasodilatory Effect of GLP-1

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03502083
Enrollment
11
Registered
2018-04-18
Start date
2015-12-01
Completion date
2017-03-01
Last updated
2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina, Stable, Coronary Stenosis, Type2 Diabetes

Brief summary

Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries

Interventions

DRUGGLP-1 (7-36)Amide

IV infusion

Sponsors

Papworth Hospital NHS Foundation Trust
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Waiting list for elective PCI to LAD Able to give informed consent Over 18

Exclusion criteria

* GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates

Design outcomes

Primary

MeasureTime frameDescription
Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baselineChange from baselineChange in coronary microcirculatory resistance from baseline
Forearm bloodflow ratio with GLP-1Change from baselinePeripheral vasodilatory response of GLP-1

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026